Back to Journals » OncoTargets and Therapy » Volume 5

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study

Authors Huang L, Li G, Zhu J, Li Z, Li T, Leng X

Received 2 March 2012

Accepted for publication 30 August 2012

Published 20 December 2012 Volume 2012:5 Pages 457—462

DOI https://doi.org/10.2147/OTT.S31387

Review by Single anonymous peer review

Peer reviewer comments 2



Lei Huang, Guang-ming Li, Ji-ye Zhu, Zhao Li, Tao Li, Xi-sheng Leng

Center of Hepatobiliary Surgery, Peking University People's Hospital, Peking University, Beijing, People's Republic of China

Background: The purpose of this study was to determine the efficacy of sorafenib in preventing and treating tumor recurrence after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria.
Methods: Thirty patients with primary hepatic carcinoma exceeding the Milan criteria underwent liver transplantation at our hospital between March 2008 and June 2010. Matched for age and gender, the patients were randomized to treatment with sorafenib 400 mg bid or capecitabine (control group, 1500 mg bid, administered for 2 weeks followed by a 2-week rest interval in each cycle). Treatments were discontinued 18 months after transplantation if no recurrence occurred. Patients who experienced tumor recurrence continued their allocated treatment until they were deemed no longer suitable for the medication. Sorafenib and capecitabine were stopped or their dose was reduced in patients with severe adverse reactions.
Results: The one-year recurrence rates were 53.3% and 86.6% in patients treated with sorafenib and capecitabine, respectively (χ 2 = 3.968, P < 0.05), and the one-year survival rates were 93.3% and 46.6%, respectively (χ 2 = 7.777, P < 0.05). Mean survival time was significantly longer in the sorafenib group (24.6 ± 1.7 [range 7– 28] months) than in the capecitabine group (16.4 ± 2.7 [range 5– 34], months (χ 2 = 7.154, P < 0.05). Most treatment-emergent adverse reactions in both treatment groups were of grade 1 or 2 in severity. The incidence of diarrhea and hand-foot syndrome tended to be higher in the sorafenib group.
Conclusion: For patients with primary hepatic carcinoma exceeding the Milan criteria, sorafenib may reduce or delay tumor recurrence after liver transplantation and prolong patient survival, with tolerable side effects.

Keywords: follow up, recurrence, targeted therapy, chemotherapy, survival rate, side effect

Corrigendum for this paper has been published

Expression of Concern for this paper has been published

Erratum for this paper has been published

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.